{{Rsnum
|rsid=4673993
|Gene=ATIC
|Chromosome=2
|position=215347616
|Orientation=plus
|GMAF=0.23
|Gene_s=ATIC,DNAPTP3
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 9.7 | 37.2 | 53.1
| HCB | 2.9 | 40.1 | 56.9
| JPT | 5.3 | 27.4 | 67.3
| YRI | 0.0 | 16.3 | 83.7
| ASW | 1.8 | 26.3 | 71.9
| CHB | 2.9 | 40.1 | 56.9
| CHD | 9.2 | 41.3 | 49.5
| GIH | 27.7 | 45.5 | 26.7
| LWK | 0.0 | 14.5 | 85.5
| MEX | 6.9 | 48.3 | 44.8
| MKK | 0.0 | 10.3 | 89.7
| TSI | 12.7 | 45.1 | 42.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=20847201
|Title=Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study
}}

{{PMID|19193698|OA=1
}} Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}